We identified a patient derived xenograft (PDX) neuroblastoma model with an ATRX p.Gly1748 mutation and treated this model with a clinically relevant dose of RA [28], 10 days after xenograft injection, and found no difference in tumour latency or growth in RA treated PDXs versus vehicle control (Fig S3A). The gene discussed is ATRX; the disease is neoplasm.